FDA批准复发性或难治性急性髓性白血病靶向治疗药物恩西地平上市
发布时间：2019-03-31 10:42
【摘要】：正2017年8月1日,美国食品和药物管理局(FDA)批准恩西地平(enasidenib,商品名:Idhifa)用于成年的因特定遗传基因突变产生的复发性或难治性急性髓性白血病(acute myeloid leukemia,AML)的治疗。FDA同时批准检测试剂盒Real Time IDH2上市,该检测试剂盒用于检测AML患者是否存在IDH2特异性基因突变。恩西地平与Real Time IDH2检测试剂盒共同使用。恩西地平由Celgene公司生产。Real Time IDH2
[Abstract]:On August 1, 2017, the U.S. Food and Drug Administration (FDA) approved Ensidipine (enasidenib, trade name: Idhifa) for adult recurrent or refractory acute myeloid leukemia (acute myeloid leukemia,) due to specific genetic mutations AML) treatment. The FDA also approved the availability of the test kit Real Time IDH2, which is used to detect IDH2-specific gene mutations in patients with AML. Encedipine is used in conjunction with the Real Time IDH2 detection kit. Ensidipine is produced by Celgene Inc. Real Time IDH2
【分类号】：R979.1
本文编号：2450831
[Abstract]:On August 1, 2017, the U.S. Food and Drug Administration (FDA) approved Ensidipine (enasidenib, trade name: Idhifa) for adult recurrent or refractory acute myeloid leukemia (acute myeloid leukemia,) due to specific genetic mutations AML) treatment. The FDA also approved the availability of the test kit Real Time IDH2, which is used to detect IDH2-specific gene mutations in patients with AML. Encedipine is used in conjunction with the Real Time IDH2 detection kit. Ensidipine is produced by Celgene Inc. Real Time IDH2
【分类号】：R979.1
【相似文献】
相关期刊论文 前2条
1 栾雪梅;;新药公告栏[J];中国处方药;2008年07期
2 王晓艳;钟磊;付晓玉;杨慧雯;李琳丽;;HPLC测定降解过程中新型靶向药物SKLB-1103的含量[J];华西药学杂志;2012年06期
，本文编号：2450831
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2450831.html
最近更新
教材专著
